PALB2 and cancer: In several retrospective analyses of next-generation sequencing (NGS) data from 23,375 patients across various common cancer types, the prevalence of multiple pathogenic/likely pathogenic (P/LP) germline mutations in homologous recombination repair (HRR) genes was analyzed.59, 60, 61 The reversion mutations were detected in BRCA1 (3.8%), BRCA2 (3.5%), and PALB2 (2.0%) after platinum-based chemotherapy and/or PARPi resistance.61